Growth Hormone Releasing Hormone (GHRH) Test in UAE | 4500 AED | DHA Licensed Laboratory

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed clinicians.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The Growth Hormone Releasing Hormone (GHRH) Test measures GHRH levels in serum to assess hypothalamic-pituitary axis integrity. It aids in diagnosing GHRH-secreting tumors and differentiating pituitary disorders such as acromegaly, gigantism, and hypopituitarism. The assay employs liquid chromatography-tandem mass spectrometry (LC-MS/MS), a validated immunoassay technique offering superior analytical sensitivity exceeding 99.9 %.

Feature	Our GHRH Test	Closest Alternative
Methodology	LC-MS/MS (validated immunoassay)	Radioimmunoassay (obsolete)
Analytical Sensitivity	>99.9%	<95%
Turnaround Time	2–3 weeks	4–6 weeks
Home Collection	ISO Cold-Chain, 8 AM–11 PM	Not guaranteed

Physician Insight & Safety Protocols

“I recognise that endocrine evaluations can feel complex and sometimes overwhelming. The GHRH level is a valuable piece of the pituitary puzzle, but it must always be interpreted alongside growth hormone (GH) and IGF‑1 for a complete clinical picture. Rely on your endocrinologist’s judgement and never alter or stop prescribed medications without explicit instruction from your treating physician.”

— Dr. Ajay Singh | General Practitioner | DHA Registration ID: 36234132

Pre-Test Advisory & Patient Preparation

Avoid all medications that may influence pituitary secretion (including glucocorticoids, somatostatin analogs, dopamine agonists) for at least 2 weeks unless medically advised otherwise.
A duly filled Test Send Out Consent Form (Form 35) is mandatory before sample collection.
Sample requirement: 3 mL (1 mL minimum) serum from one Red Top (No Additive) tube. Do not use SST gel barrier tubes. Separate serum into a sterile screw-capped vial, freeze immediately, and ship frozen. Do not thaw.

Exclusion Criteria & Emergency Red Flags

Acute febrile illness or uncontrolled severe hypertension.
Current use of medications known to interfere with pituitary secretion (discontinuation only under specialist supervision).
Pregnancy without clearance from an obstetrician or endocrinologist.
Inability to provide informed consent; minors require legal guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Sudden, severe headache with vision loss or double vision — suspect pituitary apoplexy.
Signs of adrenal crisis (severe weakness, vomiting, confusion) — seek emergency care immediately.

Patient FAQ & Clinical Guidance

1. What is the GHRH test used for?

The GHRH test evaluates pituitary function and detects GHRH-secreting tumors that cause acromegaly or gigantism. It is often part of a comprehensive pituitary work‑up in both adults and children with abnormal growth patterns.

2. How should I prepare for the GHRH test?

Avoid all medications affecting pituitary secretion for 2 weeks and provide signed Form 35 prior to collection. Fasting is not required, but you must inform the phlebotomist about all supplements and ongoing treatments.

3. What do abnormal GHRH levels indicate?

Elevated GHRH levels often point to a hypothalamic tumor driving acromegaly; low GHRH indicates pituitary deficiency. Results must be correlated with GH and IGF‑1 levels and pituitary imaging for accurate clinical interpretation.

UAE Regulatory & Data Privacy Adherence

All diagnostic services provided by DNA Labs UAE comply strictly with:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — ensuring patient data confidentiality and secure processing.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — governing digital health data exchange and electronic medical records.
Federal Decree-Law No. 4 of 2016 on Medical Liability — governing clinical testing safety, informed consent, and patient rights.
ISO 9001:2015 quality management system (Cert: INT/EGQ/2509DA/3139) for all laboratory processes.

DHA Facility License Number: 1143 | Laboratory: DNA Labs UAE

Clinical & Logistical Metadata

Test Name	Growth Hormone Releasing Hormone (GHRH) Test
Price (AED)	4,500 AED
Turnaround Time	2–3 weeks
Sample Type / Matrix	Serum (Red Top, No Additive tube) — VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM
Methodology Used	LC-MS/MS (validated immunoassay)
ICD-10-CM Code	E22.0 (Acromegaly and pituitary gigantism), E23.0 (Hypopituitarism)
LOINC Code	20985-6 (Growth hormone releasing hormone [Mass/volume] in Serum or Plasma)
DHA Facility License & Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE